safety & risk profile
side effects, cancer risk, contraindications, and quality control
What We Know and Don't Know
Ruff 2010 tolerated IV TB4 up to 1,260 mg over 14 days in a small Phase I trial -- which says nothing about the chronic subcutaneous dosing the community uses, since that trial measured acute tolerability, not long-term safety outcomes or cancer risk.
A peptide that drives angiogenesis and cell migration could, in theory, help tumors grow. TB4 is overexpressed in colorectal, pancreatic, and NSCLC tumors. Whether that means real risk at community doses is untested.
The gap is uncertainty, not proof of harm. Anyone with active cancer or strong family history should stay off.
This page is for educational purposes only and not medical advice. Consult a licensed healthcare provider before making any decisions about peptide use.
what evidence actually exists for TB-500 safety
click each tier for what the data shows.
The Cancer Question: Theoretical vs Tested
known vs assumed.
Interactive Safety Matrix
risk categories and evidence levels.
known risks vs theoretical risks
what the data actually shows vs what is merely possible but untested.
documented (human data)
- Ruff 2010: IV doses up to 1,260 mg over 14 days were well tolerated
- mild injection-site reactions reported in some subjects
- no serious adverse events in the Phase I cardiac pilot (10 patients)
- RGN-259 eye drops: mild ocular irritation in a minority of Phase 2 participants
- all human safety data is short-duration and small-sample
theoretical (unconfirmed)
- TB4 overexpressed in colorectal, pancreatic, and NSCLC tumors -- may promote tumor growth at supraphysiological doses
- angiogenic activity could theoretically support tumor vascularization
- unknown interactions with medications affecting coagulation or growth factor signaling
- gray-market products may contain impurities not present in clinical-grade material
- no long-term safety data for the chronic subcutaneous regimens the community uses
key terms
adverse effect — injection-site reaction
redness, swelling, or pain at the subcutaneous injection site. the most commonly reported side effect in the Ruff 2010 phase 1 trial, affecting a minority of subjects at higher doses.
adverse effect — tumor-promoting concern
TB4 is overexpressed in several cancer cell lines and may promote migration of malignant cells via the same ILK/Akt pathway it uses in normal tissue. the risk in humans using TB-500 is unknown.
risk assessment — gray-market quality control
TB-500 sourced from research chemical vendors has no FDA manufacturing oversight, meaning purity, sterility, and actual peptide content are unverified. contamination is a real risk.
risk assessment — long-term safety data gap
the Ruff 2010 trial measured only acute tolerability over weeks. no study has followed TB-500 users for years. chronic subcutaneous use has no safety evidence base of any kind.